Sosei maakt nieuwe hoofd Investor Relations en Corporate Communications en Group Financial Controller bekend
TOKIO–(BUSINESS WIRE)– Sosei Group Corporation (‘Sosei’; TSE Mothers Index 4565), een internationaal biofarmaceutisch bedrijf uit Japan, maakt vandaag bekend Chris Cargill te hebben benoemd tot hoofd Investor Relations en Corporate Communications en Kieran Johnson tot Group Financial Controller.
Cargill komt over van J.P. Morgan, waar hij vicepresident was voor het Britse onderdeel Healthcare Investment Banking and Corporate Broking Group. Hier focuste hij op de levenswetenschappen, inclusief de farmaceutische en biotechnologische sector. Hij neemt een schat aan ervaring mee in broking, investeerdersrelaties, kapitaalmarkten en strategisch advies.
Sosei Announces Key Appointments of Head of Investor Relations and Corporate Communications and Group Financial Controller |
|||||
|
TOKYO–(BUSINESS WIRE)– Sosei Group Corporation (‘Sosei’; TSE Mothers Index 4565), an international biopharmaceutical company originating from Japan, today announces the appointment of Chris Cargill as Head of Investor Relations and Corporate Communications and Kieran Johnson as the company’s Group Financial Controller. Mr. Cargill joins Sosei from J.P. Morgan, where he was a Vice President in the U.K. Healthcare Investment Banking and Corporate Broking Group and focused on the life sciences industry, including the pharmaceutical and biotechnology sectors. Mr. Cargill brings a wealth of experience across corporate broking, investor relations, capital markets, and strategic advisory. He began his career in the Corporate Finance M&A division of KPMG, and holds double bachelor’s degrees in law and business (banking & finance), and a Diploma in Languages (Japanese) from Monash University in Melbourne, Australia. Mr. Johnson was most recently Financial Controller for GlaxoSmithKline’s UK pharmaceuticals sales and marketing division. Over the course of his 25-plus year career, he has gained diverse international experience in financial reporting, financial compliance and M&A, and in addition worked on the creation of ViiV Healthcare, GSK’s HIV joint venture with Pfizer. Mr. Johnson commenced his accounting career at KPMG, where he spent 10 years on diversified financial and due diligence assignments specializing in pharmaceutical companies. He is a Fellow of the Institute of Chartered Accountants in England and Wales and holds a Bachelor of Science (Hons) from the University of Bath in the U.K. Commenting on the appointments, Peter Bains, CEO at Sosei, said: “I am delighted to welcome Chris and Kieran to the team as we continue to build Sosei into a global biopharmaceutical presence. Chris’ industry perspectives and experience will be crucial as we move forward with our strategic business initiatives and build our international profile. Similarly, Kieran’s global financial controls experience will enable him to play a key role leading initiatives that support our growth ambitions. I look forward to working with both Chris and Kieran in their new roles.” About Sosei Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing its GPCR structure-based drug design platform technology, Sosei has established a product pipeline with first/best in class potential. Through development and commercialization partnerships, Sosei has already delivered two bronchodilators for COPD which generate significant and stable revenue streams that enable further growth. Sosei partners include Novartis, Allergan, AstraZeneca, MedImmune, MorphoSys, Teva, and Pfizer and we are actively looking for new partnerships to enhance the development of our products and help us deliver them to patients worldwide. For further information about Sosei, please visit http://www.sosei.com/en/. Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. View source version on businesswire.com: http://www.businesswire.com/news/home/20170918006557/en/ Contacts Sosei Group Corporation |
|||||